Subjects
fractures, hypersensitivity, alcohol breath, alcohol abuse
MASSIVE BLOOD LOSS, HYPERSENSITIVITY, DISEASES, ULCERS
Eligible subjects were healthy men, aged 18-45 years, with a body mass index of 18–26 kg/mThe main exclusion criteria were as follows: (1) abnormal clinical manifestations such as the nervous system, cardiovascular system, blood and lymphatic system, immune system, digestive system, respiratory system, metabolism, bone, and other systematic diseases; (2) hypersensitivity to recombinant anti-VEGF humanized monoclonal antibody injection, Avastin® and its excipients; (3) history of antibody therapy such as bevacizumab or VEGF-targeted drugs; (4) use of any biological product or been inoculated with a live attenuated vaccine within three months of the study drug infusion or use of any monoclonal antibody within nine months; (5) participation in any clinical trial within the previous three months before signing the informed consent form; (6) history of donating and/or receiving any blood or blood products, or massive blood loss (> 450 mL) in the last three months, or plan to donate blood during the study; (7) unhealed wound ulcers or fractures or history of major surgery within two months of randomization or plan to undergo significant surgery during the study or within two months after study completion; (8) positive alcohol breath test on the day of screening or admission or a history of alcohol abuse within three months prior to screening; (9) history of smoking > 5 cigarettes per day within three months prior to enrollment.